Stifel keeps Buy on Candel and DarioHealth but cuts both price targets
Stifel kept Buy ratings on Candel Therapeutics and DarioHealth while lowering price targets to $19 and $5, according to TradingView data from November 13.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Stifel kept its Buy rating on Candel Therapeutics but reduced its price target by 13.6%, from $22 to $19. According to TradingView, the stock closed at $8.39 on November 12, and the new target implies an upside of 126.5%.
Stifel also maintained its Buy rating on DarioHealth but halved its price target, from $10 to $5. The new target implies an upside of 203% from the November 12 close of $1.65.
why it matters
Rating and target changes like these usually concern individual companies and rarely move the broader market. The key point is that in both cases the analyst lowered its valuation while keeping a positive rating, which may signal revised expectations for small biotech and medtech companies. This is the analyst's view, not investment advice.
tags
instruments
sources
- Stifel maintains Candel Therapeutics at Buy, lowers price target to $19 from $22 — TradingView, 13 November 2026 at 13:00 UTC
- Stifel maintains DarioHealth at Buy, lowers price target to $5 from $10 — TradingView, 13 November 2026 at 13:02 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗